Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06480396 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma

Study acronym: SARveillance
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 2024 to Nov 2024
    • Secondary endpoints: details revised at 2 of 3 entries
    • Site contacts updated at 2 of 2 sites
    • Study description shortened, about 1 word
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The SARveillance trial is an efficient, pragmatic, multi-centre, international, stratified, partially-randomised, patient-preference trial within a registry of high versus lower intensity radiological surveillance following primary resection of retroperitoneal, abdominal and pelvic soft tissue sarcoma. The trial design is stratified by sarcoma tumour grade (high/intermediate grade and low grade).
Trial Details
NCT Number NCT06480396
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators: University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Royal Marsden NHS Foundation Trust, University Hospital Padova, Campus Bio-Medico University, The Netherlands Cancer Institute, KU Leuven, Heidelberg University, Dana-Farber/Brigham and Women's Cancer Center, Emory University, Mayo Clinic, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, The Cleveland Clinic, M.D. Anderson Cancer Center, University of Southern California, Ohio State University, Ottawa Hospital Research Institute, McGill University, Peter MacCallum Cancer Centre, Australia, Royal Prince Alfred Hospital, Sydney, Australia
Conditions
(from sponsor)		 Sarcoma,Soft Tissue, Sarcoma Retroperitoneal
Related terms Sarcoma
Enrollment 584 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov